SecBot SecBot
Insider Cluster (3 insiders) ·Filed Aug 18, 2026

ABCL

AbCellera Biologics Inc.
BULLISH
Impact 5/10
Horizonweeks Processed3mo ago
Insider cluster: 3 insiders, $1.0M total
Actionable Insight ▲ Bullish

The CFO's open-market buy alongside two directors, coming right after a dilutive $200M offering, is a strong vote of confidence in the pipeline. Monitor upcoming ABCL635 Phase 2/3 data readouts and any further insider accumulation. The cluster buys suggest the recent offering-driven selloff may be overdone.

DirectionBullish
Confidencehigh
Horizonweeks

ABCL635

● Neutral Named in this insider cluster
Impact
Phase
Phase 2
Time to market
Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
Next catalyst
None dated

What to watchThe next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.12
T+0 close · Aug 18, 2026 · via day close
Latest settled
+7.46%
T+60 · $11.95
Vs SPY
+8.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $11.12entry
  2. T+1 · 3mo ago +8.00%α +7.79% · $12.01
  3. T+5 · 3mo ago +12.41%α +12.61% · $12.50
  4. T+20 · 2mo ago +4.95%α +6.69% · $11.67
  5. T+60 · 6d ago +7.46%α +8.46% · $11.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three AbCellera insiders, including the CFO and two directors, purchased a total of ~$975K in open-market shares over a 7-day window following a $200M dilutive offering and positive Phase 2 data for ABCL635. The cluster buys, particularly the CFO's $384K purchase, signal insider confidence in the pipeline despite the recent capital raise dilution. At ~0.03% of market cap, the dollar amount is modest but the C-suite participation and proximity to a catalyst make this a notable bullish signal.

Key Financial Metrics

Direction
buying
Total Value
$975.2K
Insiders
3

Key Facts

  • CFO Andrew Booth bought $384K in open-market shares on 2026-08-14 at $10.32
  • Director Michael R. Hayden bought $481K on 2026-08-12 at $10.37
  • Director John S. Montalbano bought $110K on 2026-08-18 at $11.03
  • Total insider purchases of ~$975K represent ~0.03% of $3.3B market cap
  • Buys occurred within 7 days of a $200M dilutive offering and positive Phase 2 data for ABCL635

Financial Impact

~$975K in insider open-market purchases, ~0.03% of market cap

insider ownership

Risk Factors

  • $200M dilutive offering will significantly increase share count and dilute existing holders
  • Insider purchases are small relative to market cap (~0.03%) and may not move the stock
  • Biotech pipeline risk, ABCL635 Phase 2 data is early and may not replicate in larger trials

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ABCL-1787079683283

Track record

16 reports on ABCL

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +127.09% at T+20 after the Jul 29, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $11.63 Now $11.12 −4.39% settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
  3. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
  4. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $12.46 Now $11.12 −10.75% settles Feb 8
  5. Aug 24, 202612w ago Insider Cluster Mixed 5/10 Entry $12.50 Now $11.12 −11.04% settles Nov 18
  6. Aug 18, 202612w ago Insider Cluster Bullish 5/10 Viewing Entry $11.12 to $11.95 Now $11.12 −0.00% ▲ +7.46% +8.46% vs SPY
  7. Aug 15, 202613w ago Institutional Cluster Bearish 6/10 Entry $11.20 to $12.46 Now $11.12 +0.71% ▼ −11.25% −14.19% vs SPY
  8. Aug 11, 202613w ago 424B5 Bearish 7/10 Entry $10.36 to $11.13 Now $11.12 −7.39% ▼ −7.48% −12.60% vs SPY
  9. Aug 10, 202614w ago 8-K Bullish 7/10 Entry $9.34 to $12.18 Now $11.12 +19.06% ▲ +30.41% +32.82% vs SPY
  10. Jul 29, 202615w ago 8-K Bullish 6/10 Entry $5.39 to $11.37 Now $11.12 +106.31% ▲ +110.95% +106.22% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (9h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 18, 2026